Nanovibronix, Inc. (NASDAQ:FEED) Short Interest Down 61.2% in May

Nanovibronix, Inc. (NASDAQ:FEED) saw a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 63,342 shares, a decline of 61.2% from the May 14th total of 163,391 shares. Based on an average trading volume of 280,633 shares, the days-to-cover ratio is presently 0.2 days. Currently, 1.1% of the shares of the stock are sold short.

Nanovibronix Price Performance

Nanovibronix stock traded down $0.05 during trading on Friday, hitting $0.83. The company’s stock had a trading volume of 459,225 shares, compared to its average volume of 1,769,525. The stock has a market capitalization of $5.05 million, a PE ratio of -0.09 and a beta of 1.51. The stock has a fifty day moving average price of $1.23. Nanovibronix has a 1-year low of $0.72 and a 1-year high of $17.40.

Nanovibronix (NASDAQ:FEED) last released its earnings results on Monday, May 18th. The company reported ($6.88) EPS for the quarter. The business had revenue of $0.65 million during the quarter. Nanovibronix had a negative net margin of 923.20% and a negative return on equity of 54.25%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on FEED. Wall Street Zen upgraded Nanovibronix from a “strong sell” rating to a “sell” rating in a research note on Tuesday, April 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nanovibronix in a research note on Friday, April 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non?invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low?intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound?care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound?care clinics, long?term care facilities and patients requiring home?based therapies.